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THERE IS NO HEALTHY LEVEL OF SMOKING
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SUMMARY - Cigarette smoking is the leading preventable cause of death in the world. Nico-
tine is a highly addictive substance. Nicotine dependence is a major barrier to successful smoking
cessation. Smoking is a risk factor for 30 diseases with a high rate of morbidity and mortality. There
is no safe level of smoking. Help and support to smoking cessation should be an integral part of
treatment, particularly for cardiovascular and cerebrovascular diseases. Prevention of smoking and
effective treatment for nicotine dependence can significantly decrease the risk of vascular and ma-
lignant diseases.
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Introduction
To quit smoking is by no means an easy task for
many smokers because of the very strong connections
relating them to cigarettes. These connections are of
both chemical and psychological nature. In fact, ciga-
rettes gradually, almost imperceptibly assume and
maintain first place on the smoker's list of priorities.
Most daily activities become inconceivable without
cigarettes. In case of cigarette shortage, smokers can
hardly overcome the unpleasant symptoms of absti-
nence. A new cigarette will then readily eliminate
their nervousness, tenseness, desire, concentration
difficulties, and other discomforts as the overt signs of
nicotine dependence. In order to avoid these discom-
forts, smokers as a rule bring cigarettes always along
and take care not to fall short of them.
Nicotine dependence poses great burden upon the
person, which is accompanied by a number of dis-
eases associated with daily tobacco smoke inhalation,
i.e. malignant, cardiovascular and cerebrovascular
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diseases. Initially, diseases associated with cigarette
smoking usually proceed without symptoms and have
already reached an advanced stage at the time of di-
agnosis. Therapeutic options are considerably reduced
due to the late detection of disease, which may result
in lethal outcome; if not, smokers frequently spend
the rest of their lives with some grade of disability.
Cigarette smoking remains the leading prevent-
able cause of death worldwide, while smoking cessa-
tion is the most cost-effective health care intervention.
Considering the magnitude and importance of the
smoking problem, the International Convention on
Smoking Control was adopted at the World Health
Organization (WHO) session held in May 2003. In
line with the Convention, the Croatian Parliament
adopted legal regulations imposing a ban on smoking
in indoor public premises in 2008, in order to prevent
passive smoking and its unquestionable consequences.
Passive smoking is not just a discomfort, but also a
direct health risk for nonsmokers.
Deciding to quit smoking is with good reason con-
sidered one of the most important decisions in one's
life. It should be firmly grounded, preferably not just
on fear, but also on the many physical, mental, social
and economic advantages associated with nonsmok-
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iq!:, Cigarette smoking is a type of dependence that
has assumed pandemic character, Nicotine is a legal-
ized drug with potent jilarmacological actien, thus
the majcdy of smokers develcp metabolic depen-
dence en nicotine w~h time, In many cases, smok-
iq!: cessatien is difficult cr even impossDle to achieve
due to jilysical or metabolic dependence en nicotine,
aleng with cencurrent psychological dependence and
firmly rooted habit of smoking, To qu ~ smoking is
not an event but a process, Many smokers manage it
after a number of attempts, whereas others are addi-
tiena11y discouraged by these falimes', The nicotine
abstinence syndrcme is a dearly defined addictien
discrder (Diagnostic and Statistical Manual of Men-
tal Discrders, DSM IV revision), which includes a
rumber of symptoms such as irr bbli ~y, frustratien,
anger, anxiety, restlessness, impatience, inscmnia and
other sleep disorders, increased awetite and weight
gain, dysphoric or depressive mood, and cencentra-
tien difficulties2, Most smokers ccrtinue smokiq!: just
because of these abstinenc e discomfcrts acccmpany-
iq!: attempts to qu ~ smoking,
Nicotine md the Brain
Nicotine is a t erti ary amine obtained frcm the
plant Nicotiana taHacum, Nicotine reach es the tnin
in only seven seccncls of tobacco smoke inhalatien and
binds to nicotinic acetylcholine aljila 4 beta 2 recep-
tcrs in the ventral t egment al area (VTA'j, resulting in
the release of the ",urotr ansmitter dcpamine irto the
rudeus accumbens, producing a flcrt-lasting pleas-
ant sensatien (nicotinic buzz) in the smoker3-',
Fig, 1. Nicotin, andth, waw,
Leng-standing repeated inhalatien of tobacco
smoke, Le, chrenic nicotine exposure results in the
activatien and desens~izatien of alpha 4 beta 2 nico-
tine acetylcholine receptors, w~h an increase in their
count', 'I};, need of nicotine increasesw~h the devel-
opmert of nicotine t olerance, Nicotine has a half-life
of enly two hours, Rapid nicotine eliminatien leads to
abstinenc e symptcms within several hours of the last
cigarette, Therefore cigarett e smokers do not make
lenger irt ervals of nonsmoking, but take every Cf'Pcr-
tunity to satisry their need ofnicotine, The unpleasant
abstinence disccmfcrts such as anxiety, tensien, rest-
lessness, etc" acccmpani ed by streng desire fcr nico-
tine, occur as SOC<l as the level of dcpamine decli",s,
Then the smoker lights another cigarette to resume
calmness and feeliq!: good, Smokers are known to
titrate their smoking habit to achieve maximal nico-
tine stimulatien whlie avoiding abstinence symptoms
and desire for nicotine,
Besides the addictive actien of nicotine, envrren-
mertal fuctcrs also playa role in the develq::mert, re-
infcrcemert and mairtenance of nicotin e dependence,
which flould be taken in coosideratien both in the
preventien of sm oking and n the process of smokiq!:
cessaticd, Behavicral science indbtes the t<ain of ad-
dicts to be atne<ma11y ccnclitiooed, Cigarett e smokiq!:
is largely associat ed with certain s ~uatioos, places and
r ~uals (e,g" opening the box, ligl-ting the cigarette,
watchiq!: smoke riq!:s, sme11iq!:)' when desire fcr ciga-
rett e is present irrespective of dcpamine level.
Dep endence Identification
Acccrding to D SM IV criteria, nicotine depen-
dence is present if three or mcr e of the following
symptcms are reccrded dur ing a ene-year period:
nicotine tolerance (decreased actien and need for
dose increase to achieve the same effect),
abstinence symptcms upen smokiq!: cessatien,
persisting desire fcr smoking in sp ~e of all effcrts
at dose reductien,
wasting an enormous amount of time fcr smoking
and buying cigarettes,
postpening wcrk, social cr recreational activ~ies
for smoking, and
cent iming smoking in spite of health disccm-
forts,
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Short Intervention
smokers in their efforts at smoking cessation should be
integrated in regular therapeutic procedures performed
by physicians at hospitals and outpatient clinics.
WHO recommends short intervention according
to which every patient should be asked whether he/
she is smoking, and if so to advise smoking cessa-
tion, evaluate his/her readiness to do it immediately
or within a month, help him/her determine the date
of smoking cessation, and follow-up the course of ab-
stinence, briefly a five-A schedule:
In most cases, abstinence poses no problem for
smokers in the acute stage of disease; however, many
smokers resume smoking upon termination of the
acute stage of disease. Short intervention by the phy-
sician generally proves inadequate in smokers with
long-standing smoking habit, great number of ciga-
rettes in their history, high-grade dependence, and
failing attempts at smoking cessation. In such cases,
a complex procedure is required, including the use
of pharmacological agents in addition to behavioral
approach. WHO recommends a combination of be-
havioral and cognitive strategy with the use of agents
intended for the management of cigarette dependence






Pharmacological Agents in the Treatment of Nicotine
Dependence
The new non-nicotinic agent Vareniklin, developed
and approved exclusively for the treatment of nicotine
dependence and registered in Croatia in 2009, has
proved significantly more efficient in the management
of nicotine dependence as compared with nicotine
substitution therapy and bupropione, previously used
in the treatment of this type of dependence'". Vare-
niklin has a logical mechanism of action. It binds to
the same acetylcholine nicotine receptors in the brain
as nicotine and leads to partial dopamine release (ago-
nist action), thus reducing the desire for nicotine and
other abstinence symptoms. If the smoker using Va-
reniklin lights a cigarette, the sensation ofdelight and
satisfaction associated with cigarette smoking will fail
Disease and Risk Factor
Cigarette smoking dependence is a chronic relaps-
ing disease that frequently requires repeat interven-
tions and multiple attempts at smoking cessation. At
the same time, cigarette smoking has been identified
as a major risk factor for some thirty diseases, as dem-
onstrated by numerous epidemiological, clinical and
experimental studies. The diseases associated with
cigarette smoking include diseases of almost all organ
systems. Respiratory system is, logically, at highest
exposure to the action of tobacco smoke because of
direct contact with the numerous and heterogeneous
toxic substances of tobacco smoke. Tobacco smoke
contains about 4000 different chemical substances
that simultaneously enter the body upon smoke in-
halation to be transported by blood to particular or-
gans. Tobacco smoke contains some 300 substances
with carcinogenic potential. Malignant, cardiovascu-
lar and cerebrovascular diseases occupy the first three
positions on the list of morbidity and mortality in
Croatia and worldwide. Cigarette smoking has been
identified as a major individual risk factor for all these
three groups of diseases. A combination of cigarette
smoking with other risk factors significantly increases
the likelihood of disease development and poor, fre-
quently fatal disease outcome.
In Croatia, stroke ranks high, third cause of death
and first cause of disability. It is widely known that,
according to statistical data, one third of stroke pa~
tients recover, one third die, and one third survive
with a minor or major disability. Many researchers
have focused their studies on the treatment and pre-
vention of stroke. New potential risk factors that con-
tribute to the development of cerebrovascular disease
are discovered on a daily basis. It seems that more ef-
forts are invested in the detection of risk factors than
in the use of efficient measures to eliminate removable
risk factors and provide better control of those that
cannot be eliminated.
Cigarette smoking definitely increases the risk of
stroke and contributes to poorer treatment outcome. It
is therefore necessary to prevent smoking, in order to
reduce maximally the proportion ofyoung people start-
ing smoking, thus remaining beyond the risk groups.
On the other hand, considering that many smokers
wish to quit smoking, but only a minor proportion
manage it on their own, the support and help offered to
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because nicotine cannot induce new dopamine release
since the respective receptors have already been oc-
cupied by Vareniklin (antagonist action). Vareniklin
therapy takes twelve weeks.
Cigarette Smoking and Cerebrovascular Disease
Results of the Framingham Study that included
4255 subjects of both sexes, aged 36-68, followed-up
for 26 years, suggest significant contribution of ciga-
rette smoking to the occurrence of stroke, with the
risk of stroke increasing with the number of cigarettes
used daily. In heavy smokers (,,40 cigarettes daily),
the relative risk of stroke was twofold that in mod-
erate smokers (<10 cigarettes daily). At two years of
smoking abstinence, the risk of stroke decreased sig-
nificantly, and at five years of smoking abstinence the
risk of stroke in former smokers was equal to the risk
recorded in nonsmokers".
It is estimated that 12% to 14% of all stroke deaths
are associated with cigarette smoking. In addition
to smoking itself being a significant risk factor for
stroke, in association with other known risk factors
it potentiates their adverse effects. The acute effect of
smoking on the circulatory system manifests as vaso-
constriction and an increased likelihood of thrombus
formation. The chronic effects of smoking are related
to the atherogenic potential of smoking and progres-
sive development ofatherosclerosis" . The mechanisms
of nicotine action are more or less known, whereas
the action of some other tobacco smoke constituents
and their interactions remain relatively obscure. En-
dothelial dysfunction and lesions '>, significantly el-
evated level of circulating tissue factor in atheroscle-
rotic plaques!', significantly higher leukocyte count,
which has been related to cardiovascular events", and
a considerably higher level of free F2 isoprostane as
an index of lipid peroxidation" have been recorded in
cigarette smokers as compared with nonsmokers.
Smoking accelerates the progression of athero-
sclerotic process in carotid arteries". The progressive
course of carotid artery atherosclerosis was demon-
strated not only in active smokers, but also in non-
smokers exposed to passive smoking.
In women, the risk of lethal stroke outcome is
considerably greater in female smokers than in female
nonsmokers sustaining a stroke. The risk oflethal out-
come increases with the number of cigarettes taken
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daily (2.5 in women taking up to 14 cigarettes daily
vs. 3.8 in those with 25 or more cigarettes daily)!'. In
a study of lethal stroke outcome in men, smokers had
a significantly greater risk oflethal outcome than non-
smokers with stroke".
The risk of hemorrhagic stroke due to either in-
tracerebral or subarachnoid hemorrhage is increased
in smokers". On the other hand, positive correlation
was found between smoking cessation and reduction
in the risk of stroke.".
Passive Smoking
Attention has been increasingly paid to the phe-
nomenon of passive smoking, along with increasing
concern about health risks to which some individuals
may be exposed against their will, being for numerous
reasons forced to inhale tobacco smoke. A nonsmoker
found in some indoor premises together with smok-
ers inhales tobacco smoke exhaled by smokers, along
with the smoke blown off from the tip of the cigarette
into the air. Passive smoking does not only mean a
discomfort, but a direct health risk. Passive smoking
increases the risk of developing some thirty diseases
including stroke, which are directly associated with
cigarette smoking. Nonsmokers at long-standing and
intensive exposure to tobacco smoke as passive smok-
ers have the same level of cotinine, a nicotine metabo-
lite, as smokers taking up to ten cigarettes daily", De-
termination of the mean coronary flow velocity reserve
(CFVR) in nonsmokers exposed to passive smoking
showed significantly lower mean CFVR upon second
hand smoke inhalation-".
The Benefits ofSmoking Cessation
There are numerous benefits of smoking cessation,
classified into several groups, i.e. physical, emotion-
al, social and financial advantages. According to the
time at which they become evident and experienced
by the ex-smoker or demonstrated by some specific
tests, these advantages are classified into the benefits
that are observable immediately upon smoking ces-
sation or after a short time of abstinence, and long-
term benefits associated with smoking cessation. The
latter include gradual reduction of the risk of disease
development, improved course of the existing disease,
and reduced risk of disease complications and lethal
outcome.
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A decrease in plasma fibrinogen concentration
and a reduced fibrinogen synthesis were found after
two-week abstinence from smoking". Another study
reports on a decrease in platelet aggregation also af-
ter two-week abstinence from smoking>'. According
to a study published in Nicotine Tobacco Research,
the 17-week abstinence from smoking resulted in nor-
malization of leukocyte count, improvement of lipid
profile, increase in the level of protective high-density
lipoprotein (HDL) and decrease in the level ofathero-
genic low-density lipoprotein (LDL) demonstrated in
ex-smokers". Cessation of smoking is associated with
improvement in the hemodynamic parameters of ar-
terial blood pressure and heart action.".
The many benefits of smoking cessation include
reduction in the risk of stroke, recurrent post-stroke
coronary events, death from cardiac arrhythmia fol-
lowing myocardial infarction, death after aortocoro-
nary bypass, and death after PTCA. The levels of
inflammatory markers associated with progression of
vascular disease, i.e. C-reactive protein, leukocytes
and fibrinogen, decrease upon smoking cessation27,28.
Prevention of smoking and treatment of nicotine
dependence also imply prevention of some thirty dis-
eases associated with smoking, including those occu-
pying the first three positions on the list of morbidity
and mortality in Croatia and worldwide, i.e. cardio-
vascular, malignant and cerebrovascular diseases.
There is no healthy level of smoking because each
cigarette smoke contains 4000 different chemicals,
some fifty of them with carcinogenic action. Each
cigarette impairs breathing, paralyzes ciliary appara-
tus, causes oxygen deprivation, narrows blood vessels,
accelerates heart action and elevates blood pressure,
exerts biphasic effect on the central nervous system,
impairs health in those found in the same room with
the smoker, and leads to dependence or reinforces it if
already present.
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Sazetak
NE POSTOJI ZDRAVA RAZINA PUSENJA
N Cop-Blaiiii L Zavoreo
Pusenje [e vodeci preventabilni uzrok smrti u svijetu. Nikotin [e izrazito adiktivan. Ovisnost 0 nikotinu je glavna pre-
preka za uspjesni prestanak pusenja. Pusenje je nzicni cimbenik za tridesetak bolesti s visokim pobolom i smrtnoscu. Ne
postoji sigurna razina pusenja. Neophodno [e integrirati pomoc i potporu za prestanak pusenja u redovitu terapiju, pogo-
tovo tijekom hjecenja kardiovaskularnih i cerebrovaskularnih bolesti. Prevencija pusenja i ucinkovito lqecenje nikotinske
ovisnosti mogu znacajno smanjiti rizik obolijevanja od vaskularnih i malignih bolesti.
Kljucne rijeci: Pusenje - stetni ucinci; Pusenje - prevenciJa i kontrola; Gneiis/enje duhanskim dimom; Zdravstveno stanje;
Cerebrovaskularne bolesti - riricni Cimbenici
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